Bryan T. Kelly, MD, MBA President and Chief Executive Officer | Hospital for Special Surgery
Bryan T. Kelly, MD, MBA President and Chief Executive Officer | Hospital for Special Surgery
Medscape reports that orthobiologics are an advancing field in orthopedics and regenerative medicine. These treatments, derived from biological substances, are used to alleviate pain associated with orthopedic conditions and may delay the need for joint replacement surgery. They also assist in healing after orthopedic procedures. While several orthobiologics have been approved by the US Food and Drug Administration (FDA), they lack specific indications and thus are not covered by insurance, making them inaccessible to many patients.
The medical device company Lipogems is conducting two Investigational Device Exemption (IDE) studies in the United States using microfragmented adipose tissue (MFat) for treating knee osteoarthritis (OA). Tsun Sean Law, MD, director of clinical research at HSS Florida, discusses the two IDE trials, ARISE and ARISE2, along with other orthobiologics being explored as OA treatments.
Alerts Sign-up